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We investigated the effect of cefotaxime and chloramphenicol on endotoxin concentra-
tions in cerebrospinal fluid (CSF) and on the development of brain edema in rabbits with
Escherichia coli meningitis. Both antibiotics were similarly effective in reducing bacterial
titers. Cefotaxime, but not chloramphenicol, induced a marked increase of endotoxin in
CSF, from log., 1.5 ± 0.8 to log., 2.8 ± 0.7 ng/ml (P < .01). This result was associated
with an increase in brain water content (405 ± 12 g of water/loo g of dry weight com-
pared with 389 ± 8 g in untreated controls; P < .01), whereas in animals treated with
chloramphenicol, brain water content was identical to controls. The cefotaxime-induced
increase in endotoxin concentration and brain edema were both neutralized by polymyxin
B, which binds to the lipid A moiety of endotoxin, or by a monoclonal antibody to lipid
A. These results indicate that treating gram-negative bacillary meningitis with selected
antibiotics induces increased endotoxin concentrations in CSF that are associated with
brain edema.
Bacterial meningitis remains a serious disease as-
sociated with high morbidity and mortality [1].The
infecting organism appears to be a major deter-
minant of the prognosis [2], which is particularly
grave in gram-negative bacillary meningitis [3, 4].
Liberation of harmful bacterial products as a con-
sequence of treatment is a possible explanation for
an adverse outcome despite effective antimicrobial
therapy. In experimental meningitis, fragments of the
pneumococcal cell wall can induce profound inflam-
mation [5, 6], increased intracranial pressure, and
brain edema [7]. Furthermore, in vitro and in vivo
experiments have demonstrated that some antibiot-
ics liberate large amounts of endotoxin from gram-
negative bacteria [8-10]. Endotoxin has been clearly
linked to many of the systemic and local complica-
tions of gram-negative infections [11]. In gram-
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negative bacterial meningitis, endotoxin is consis-
tently found in CSF at the time of diagnosis [12].
During therapy, endotoxin concentrations in the CSF
decline progressively over a period of days, but the
possibility of an initial rise of endotoxin, after in-
stituting antibiotics, has not been excluded [12].
Endotoxin release from bacteria into CSF during
treatment of gram-negative bacillary meningitis may
induce harmful effects on the brain. The present
studies were designed to determine whether antibi-
otic treatment induces an increase of endotoxin in
CSF and whether this increase is associated with
harmful pathophysiological effects in a model of
Escherichiacoli meningitis. Results demonstrate that
endotoxin concentrations increased with one antibi-
otic but not a second antibiotic and that this increase
was associated with the development of brain edema.
This effect was aborted by polymyxin B,which binds
to the active moiety of endotoxin (lipid A), and by
monoclonal antibodies to lipid A.
Materials and Methods
Infecting organism. A Kl-positive, serum-
resistant strain of E. coli, originally isolated from
a neonate with meningitis, was used. The organism
was stored on glass beads at - 70 C, grown overnight
in tryptic-soy broth, and then washed and diluted
in saline to the desired concentration. MIC/MBCs
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of the organism were 0.125/0.125 ug/ml for cefotax-
ime and 8/>64 ug/rnl for chloramphenicol [13].
Model of experimental meningitis. We used a
rabbit model of experimental meningitis, which was
originally described by Dacey and Sande [14]. In
brief, New Zealand white rabbits, 2-3 kg, were
anesthetized iv with 30 mg of pentobarbital/kg
(Carter-Glogau Laboratories, Glendale, Ariz). A
dental acrylic helmet was attached to the skull by
using four screws; the helmet allowed the animals
to be placed in stereotactic frames constructed to
facilitate puncture of the cisterna magna. Three days
after attachment of the helmet, the animals were
again anesthetized with pentobarbital, and 5-7 x
lOS cfu of logarithmically growing E. coli suspended
in 0.3 ml of saline were injected into the cisterna mag-
na by using a spinal needle (3.5 inch, 25 gauge; Bec-
ton, Dickinson and Co., Rutherford, NJ). Sixteen
hours later, long-lasting anesthesia was induced by
iv infusion of 2 g of urethane/kg (Sigma, St. Louis).
The animals were placed in the stereotactic frames,
the cisterna was punctured to collect the first sam-
ple of 0.3 ml of CSF, and treatment was started
through an iv line placed in a peripheral ear vein.
On individual days, groups of six rabbits were ex-
amined. The animals wereusually assigned to at least
three different treatment or control regimens.
Treatment regimens. Antibiotic therapy con-
sisted of a 3-hr constant infusion, beginning 16 hr
after infection, with cefotaxime or chlorampheni-
col. Infusions were started with a bolus injection
equivalent to the amount of drug infused per hour.
Antibiotics were administered in doses that would
achieve the high CSF concentrations necessary for
a rapidly bactericidal action [13, 15]:cefotaxime was
infused at a dosage of 100mg/kg per hr and resulted
in CSF steady-state concentrations of rvl0-15 ug/rnl
[13]; chloramphenicol was administered at a dosage
of 60 mg/kg per hr and resulted in CSF concentra-
tions of rv12 ug/rnl [13, 16].
Neutralization ofendotoxin in CSR We exam-
ined the neutralization of endotoxin in CSF by poly-
myxin B, which binds nonspecifically to the lipid A
moiety of endotoxin [17], and by a monoclonal an-
tibody directed against lipid A. Starting 16 hr after
infection, polymyxin B was infused for 3 hr at a dos-
age of 5,000 U/kg per hr, either simultaneously with
antibiotic treatment (cefotaxime) or alone. This dos-
age was chosen because it produced CSF concentra-
tions (4.0 ± 1.0mg/liter) that wereeffectivein reduc-
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ing the endotoxin activity without reducing the CSF
bacterial titers.
The monoclonal antibody was produced by fusion
of an Epstein-Barr virus-transformed peripheral
monocyte with a human fusion partner. Details of
the generation and characterization are described
elsewhere [17a]. The IgM antibody was found to bind
to lipid A of all 15 strains of E. coli and Salmonella
tested, including the organism used in this study. The
antibody was administered either alone or simultane-
ously with antibiotic treatment (cefotaxime). Ap-
proximately 100 J.1g of antibody was injected twice
intracisternally in 0.3 ml of PBS, 16 and 17.5 hr af-
ter infection. This quantity of antibody was chosen
because it produced concentrations in CSF that, on
the basis of in vitro results, would be sufficient to
neutralize the amount of endotoxin released by the
E. coli.
CSF examination. Bacterial titers in CSF were
determined by overnight incubation of serial dilu-
tions on blood agar plates. CSF endotoxin concen-
trations were determined in twofold serial dilutions
of CSF in pyrogen-free water [8]. A commercially
available Limulus amebocyte lysate test (Pyrotells;
Associates of Cape Cod, Woods Hole, Mass) was
used to determine the presence of detectable endo-
toxin, and the manufacturer's guidelines were ob-
served. The lower limit of detectability of endotoxin
was 3 pg/ml. In the monoclonal antibody prepara-
tion, the Limulus amebocyte lysate test indicated a
minimal endotoxin content of 0.12 ng/ml. No en-
dotoxin activity was detected in the antibiotics tested.
Brain water content (edema). At the end of the
experiment, 19hr after infection, animals were killed
by an iv overdose of pentobarbital. As described in
detail earlier [18], the brain was immediately removed
and dissected on filter paper. One hemisphere was
weighed and then dried to stable dry weight in a
vacuum oven at 105 C. The other hemisphere was
dissected into gray and subcortical white matter, and
these fractions were also weighed and dried. Brain
water content was expressed as grams of water per
100g of dry weight. Using these techniques, wefound
that homologous hemispheres differed by an aver-
age of 3.5 g of water/Itx) g of dry weight [18].
Statistics. Results are expressed as mean ± SD.
Paired comparisons of groups were performed by
using the two-tailed Student's t test, and multiple
comparisons between groups were performed with
the Newman-Keuls test [19]. Correlation coefficients
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Table 1. Bacterial titers and endotoxin concentration in CSF associated with brain edema in rabbits with E. coli
meningitis.
16 Hr postinfection 19 Hr postinfection
Treatment group (n) Titer'" Endotoxin'[ Titer'" Endotoxin'l Edemaf
Uninfected (8) 382 ± 8
Infected controls (16) 4.5 ± 1.1 1.2 ± 0.9 5.1 ± 1.1 1.3 ± 0.7 389 ± 8
Cefotaxime (15) 5.2 ± 1.0§ 1.5 ± 0.8§ 2.6 ± 2.0 2.8 ± 0.711 405 ± 1211
Chloramphenicol (7) 4.6 ± 0.9 1.0 ± 0.7 2.7 ± 2.0 1.5 ± 0.8 389 ± 9
NOTE. Results are expressed as mean ± SD.
'" Log., cfu/ml.
t Log., ng/rnl.
t Brain edema, g of water/loo g of dry weight.
§ Not significant compared with corresponding values in animals treated with chloramphenicol.
II P < .01 compared with corresponding values in other groups.
weredetermined by the least-square linear regression
method.
Results
Sixteen hours after intracisternal infection, rabbits
showed signs of meningitis, with lethargy, elevated
body temperature (>40 C), CSF pleocytosis with a
predominance of neutrophils, and positive CSF cul-
tures for E. coli (l(P-I06 cfu/ml; tables 1 and 2). In-
fection in the subarachnoid space was accompanied
by measurable endotoxin concentrations in the CSF,
with mean values in the experimental groups rang-
ing from 10 to 100 ng/ml (tables 1 and 2).
If left untreated, animals had slightly higher titers
and endotoxin concentrations in CSF after three ad-
ditional hours (table 1). By this time (19 hr after in-
fection) animals were killed, and brain water con-
tent was determined. Brain water content was higher
in infected animals than in uninfected controls (hemi-
spheres, 389 ± 8 vs. 382 ± 8 g of water/loo g of
dry weight; P = .08).
Both antibiotics used in the study, cefotaxime and
chloramphenicol, reduced CSF bacterial titers to
similar degrees when infused for 3 hr (mean reduc-
tion, log., 2.6 and 1.9cfu/ml, respectively; table 1).
The effect of the two drugs on the endotoxin con-
centration and brain water content at the end of treat-
ment was, however, markedly different (table I).
'Ireatment with chloramphenicol was associated with
a slight increase of borderline significance (P < .1)
in CSF endotoxin concentrations. Treatment with
cefotaxime, however, was followed by a much more
pronounced increase of endotoxin in the CSF, with
final concentrations "-'10times higher than that ob-
tained with chloramphenicol (P < .01). Chloram-
Table 2. Influence of endotoxin neutralization on brain edema in cefotaxime-treated rabbits with E. colimeningitis.
16 Hr postinfection 19 Hr postinfection
Bacterial Bacterial
Treatment group (n) titer" Endotoxint titer" Endotoxint Edemat
Uninfected (8) 382 ± 8
Infected controls (16) 4.5 ± 1.1 1.2 ± 0.9 5.1 ± 1.1 1.3 ± 0.7 389 ± 8
Cefotaxime (15) 5.2 ± 1.0 1.5 ± 0.8 2.6 ± 2.0 2.8 ± 0.7§ 405 ± 12§
Cefotaxime + polymyxin (12) 5.0 ± 1.1 1.2 ± 0.8 2.5 ± 1.311 0.6 ± 1.0§ 392 ± 8 §
Cefotaxime + MAb (11) 4.8 ± 1.5 2.0 ± 1.5 1.2 ± 1.511 1.6 ± 1.0§ 382 ± 8§
Polymyxin (6) 4.9 ± 1.2 1.8 ± 0.9 4.7 ± 1.5 1.3 ± 1.6 395 ± 10
MAb (6) 3.7 ± 2.3 1.3 ± 1.0 4.7 ± 1.8 1.1 ± 1.1 378 ± 3
NOTE. Results are expressed as mean ± SD.
'" Log., cfu/ml.
t Log., ng/ml.
t Brain edema, g of water/loo g of dry weight.
§ P < .01, cefotaxime vs. others.
II Not significant.
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phenicol did not induce brain edema above that ob-
served in infected, untreated control animals,
whereas treatment with cefotaxime was followed by
a significant rise in brain water content (hemispheres,
405 ± 12 vs. a mean of 389 in the two other groups;
P < .01, table 1).
Intravenous infusion of polymyxin B for 3 hr pro-
duced a bacteriostatic effect on E. coli, and CSF en-
dotoxin concentrations and brain water content were
similar to untreated, infected controls (table 2).
When polymyxin B was infused simultaneously with
cefotaxime, the cefotaxime-associated increase of en-
dotoxin in the CSF and the associated possible brain
edema were eliminated (table 2).
A similar effect was observed with a monoclonal
IgM antibody to lipid A. The antibody had no ef-
fect on CSF bacterial counts; titers rose from log.,
3.7 ± 2.3 to 4.7 ± 1.8 cfu/ml between 16 and 19
hr after infection. During the same period, the mea-
surable endotoxin concentration in CSF decreased,
and the final brain water content was reduced (hemi-
spheres, 378 ± 3 g of water/l00 g of dry weight; ta-
ble 2). Injecting the antibody intracisternally dur-
ing cefotaxime treatment of infected animals reduced
both the measurable endotoxin concentration and
the brain water content, with the latter reaching
values comparable to those in uninfected controls
(table 2).
The association of endotoxin release and the de-
velopment of brain edema was supported by the posi-
tive correlation found between CSF endotoxin con-
centrations 19 hr after infection and the degree of
brain edema (r = .28, n = 73; P = .03). Brain edema
predominantly developed in the subcortical white
matter. Water content was clearly highest in the white
matter of animals treated with cefotaxime alone (267
± 20 g of water/l00 g of dry weight, compared with
235 ± 8 g of water/l00 g of dry weight in uninfected
controls; P< .01), which corresponds to an increase
of 14070. Differences in gray matter water content
were less pronounced. Nevertheless, animals treated
with cefotaxime alone also had the highest water con-
tent in gray matter (445 ± 18 g of water/l00 g of
dry weight compared with 430 ± 7 g of water/l00
g of dry weight in controls; P < .06).
Discussion
This study provides important new information
about the pathophysiology of bacterial meningitis
and has potential relevance for the therapy of gram-
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negative bacillary infection. The results suggest that
treating E. coli meningitis with some, but not all, an-
tibiotics is associated with a marked increase of CSF
endotoxin concentrations early after beginning ther-
apy. The endotoxin induces a significant increase in
brain edema; this effect can be blocked by selective
binding of the lipid A component of endotoxin.
A major focus in the antimicrobial treatment of
bacterial meningitis and other serious infections has
been the need to achieve a rapid bactericidal action
[20-22]. Almost from the beginning of the antibi-
otic era, however, there has been concern that rapid
lysis of gram-negative organisms could be detrimen-
tal to the host [23]. Recent work [8-10] has provided
evidence for this concern. Antibiotics in vitro, as well
as in a rabbit model ofgram-negative sepsis, induced
marked release of endotoxin. The present study ex-
tends these findings to a model of gram-negative
bacillary meningitis and correlates the changes in en-
dotoxin concentrations in the CSF with a patho-
physiological parameter. The two antibiotics stud-
ied differed substantially in their effect on endotoxin
concentrations in the CSF. Chloramphenicol, an in-
hibitor of bacterial protein synthesis, induced only
a small increase of endotoxin in our model of menin-
gitis and in the rabbit model of gram-negative sep-
sis [10]. However, a cell wall-active cephalosporin,
cefotaxime in our study and moxalactam in the sep-
sis model [10], induced a large increase in endotoxin
concentration.
Endotoxins are responsible for many of the
pathophysiological effects of gram-negative infec-
tions (reviewed by Morrison and Ulevitch [11] and
by Ryan [24]). The lipopolysaccharide molecules in-
teract with humoral and cellular systems and lead
to fever, septic shock, disseminated intravascular
coagulation, adult respiratory distress syndrome, and
other complications of gram-negative infections. The
effect of endotoxin on the brain in gram-negative
meningitis has not been previously studied.
Brain edema is a common and potentially fatal
complication of bacterial meningitis. In experimental
pneumococcal meningitis, we have previously docu-
mented a consistent rise in the brain water content
as a consequence of the infection in the subarach-
noidal space [18]. Treatment with antibiotics or corti-
costeroids reverses this increase in brain water con-
tent [18]. Similar changes in brain water content that
are caused by live pneumococci can also be induced
by injecting bacterial cell wall products [7]. The pres-
ent study demonstrates that the apparent liberation
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of endotoxin by antibiotic treatment of E. coli men-
ingitis is associated with a dramatic increase in brain
water content. This development of brain edema
takes place predominantly in the subcortical white
matter, a localization that is indicative of vasogenic
brain edema [25]. Endotoxin damages endothelial
cells directly [26, 27] or by stimulating granulocytes
[28]. Morphological alterations of the endothelium
of the blood-brain barrier (opening of the tight junc-
tions between the endothelial cells) and increased
permeability to proteins and fluid are consistent find-
ings in meningitis [29]. In the case of gram-negative
meningitis, it is thus likely that endotoxin damages
the endothelium of the cerebral capillaries (blood-
brain barrier); this damage subsequently leads to vas-
cular leakage and the development of vasogenic
brain edema.
The molecular structure of the endotoxin respon-
sible for the majority of its harmful effects is the
lipid A portion of the core region [12, 24]. It is well
established that inactivation of lipid A prevents many
of the endotoxin-mediated biologic effects in vitro
and in vivo. Polymyxin B, a cyclic polypeptide anti-
biotic that binds to lipid A [17], has been used suc-
cessfully to this end [30-33], although not all func-
tions of endotoxin can be neutralized by polymyxin
B [34]. In a recent study of experimental meningitis,
preincubating polymyxin B of Haemophilus influen-
zae type b lipopolysaccaride reduced the potential
of the lipopolysaccharide to induce an inflammation
in the CSF [35]. In the present study, polymyxin B
prevented the increase, in the CSF, of measurable en-
dotoxin induced by cefotaxime and also reduced the
associated increase in brain edema. This finding sup-
ports the essential role of endotoxin in the develop-
ment of brain edema associated with cefotaxime
treatment, because polymyxin B alone had no effect.
Antibodies to the glycolipid core region of endo-
toxin have attracted major attention as tools in the
prevention or treatment of the septic complications
associated with gram-negative bacteremia [36, 37].
Because the core region of lipopolysaccarides of
different gram-negative bacteria is relatively stable
immunologically, antibodies to the core region of
one strain are protective against the endotoxin of
different strains [38, 39]. More recently, monoclo-
nal antibodies against the core region of endotoxin
have been developed; these antibodies also show
cross-reactivity [40]. In this study we used a mono-
clonal IgM antibody to lipid A with cross-reactivity
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to lipid A of several E. coli and Salmonella strains
(data not shown). Injecting this antibody into the
CSF protected against a cefotaxime-associated in-
crease in endotoxin and brain edema. This finding
strongly supports the concept that the lipid A por-
tion of endotoxin was responsible for the develop- .
ment of brain edema in our model ofE. coli menin-
gitis. It is interesting that the monoclonal antibody
did not differ from polymyxin B in its capacity to
neutralize measurable endotoxin in the CSF, but was
clearly more effective in reducing brain water con-
tent. This could imply an additional nonspecific ef-
fect of the IgM macromolecule beyond its protec-
tive action against lipid A. We also found a slight
reduction of brain edema with another IgM antibody
not directed against endotoxin (data not shown), and
these macromolecules may have some hypertonic ef-
fects on brain water content.
Our study examined neither the mechanisms
responsible for the increase, in CSF, of endotoxin
concentrations associated with cefotaxime treatment
nor the molecular basis of the effect of polymyxin
B or the monoclonal antibody. Moreover, the clini-
cal relevance of our findings is not fully established.
Nevertheless, it appears likely that brain edema in
bacterial meningitis contributes to morbidity and
mortality and that a potentiation by endotoxin may
be harmful [25, 41]. Interestingly, >50070 of the brain
herniations in the series of bacterial meningitis
reported by Dodge and Swartz [41] occurred >2 hr
after lumbar puncture, at a time when therapy pre-
sumably had been initiated. Conceivably, endotoxin-
induced brain edema may have played a role in some
of these cases. Further studies will be necessary to
elucidate the mechanisms responsible for both the
increase and inactivation of endotoxin documented
in this study and to explore the value of therapeutic
strategies that block the release of potentially dele-
terious bacterial products or inactivate their effect
on the host.
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